Comparative Pharmacology
Head-to-head clinical analysis: EMPAGLIFLOZIN LINAGLIPTIN versus NESINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMPAGLIFLOZIN LINAGLIPTIN versus NESINA.
EMPAGLIFLOZIN; LINAGLIPTIN vs NESINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor that reduces renal glucose reabsorption, increasing urinary glucose excretion. Linagliptin is a dipeptidyl peptidase 4 (DPP-4) inhibitor that prolongs the activity of incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
10 mg empagliflozin/5 mg linagliptin orally once daily.
25 mg orally once daily.
None Documented
None Documented
Empagliflozin: ~12.4 h (supports once-daily dosing). Linagliptin: ~12 h (terminal half-life; long binding to DPP-4 allows once-daily dosing despite short half-life).
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Empagliflozin: ~54% renal (unchanged), ~41% fecal (primarily unchanged parent). Linagliptin: ~80% fecal (enterohepatic circulation), ~5% renal.
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Category A/B
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor